文献速递心力衰竭与心肌病心律失常

非缺血性心肌病患者的一级预防植入式心律转复除颤器:一项Meta分析

Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该Meta分析检索2000年1月1日至2016年10月31日的PubMed等来源,纳入4项随机临床试验共1874例非缺血性心肌病患者(ICD组937例,对照组937例),评估一级预防ICD与全因死亡率的关系。汇总分析显示ICD显著降低全因死亡率(HR 0.75,95%CI 0.61-0.93,P=.008;异质性P=.87),作者认为该结果支持相关专业指南推荐在此类患者中使用ICD。

要点

  • 4项随机临床试验共1874例非缺血性心肌病患者,ICD组与对照组各937例。
  • 一级预防ICD显著降低全因死亡率(HR 0.75,95%CI 0.61-0.93,P=.008)。
  • 作者认为该结果支持专业指南推荐在此类患者中使用ICD。

核心结论

  • 一级预防ICD可有效降低非缺血性心肌病患者的全因死亡率。
  • 作者认为这些发现支持专业指南推荐在此类患者中使用ICD。

研究设计与样本

  • 研究为Meta分析,检索PubMed自2000年1月1日至2016年10月31日,并补充相关文献参考文献及专家咨询。
  • 纳入标准为随机临床试验设计、比较ICD与药物治疗(对照)、至少100例非缺血性心肌病患者、报告至少12个月随访的全因死亡率、以英文发表。
  • 共纳入4项随机临床试验,1874例独特患者,ICD组937例,对照组937例。
  • 采用PRISMA指南提取数据并评估数据质量与有效性,使用固定效应和随机效应模型汇总数据。

主要发现

  • 汇总4项试验显示,ICD组较对照组显著降低全因死亡率(HR 0.75,95%CI 0.61-0.93,P=.008)。
  • 异质性检验P=.87。

关键数值与推荐

  • 主要终点为全因死亡率。
  • 数据收集开始前假设一级预防ICD可降低非缺血性心肌病患者的全因死亡率。

临床怎么用

  • 作者认为这些发现支持专业指南推荐在此类患者中使用ICD。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. OBJECTIVE: To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. DATA SOURCES: PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. STUDY SELECTION: Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1 met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. DATA EXTRACTION AND SYNTHESIS: The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed- and random-effects models. MAIN OUTCOMES AND MEASURES: The primary end point was all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. RESULTS: Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P = .008; P = .87 for heterogeneity). CONCLUSIONS AND RELEVANCE: Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. JAMA Cardiol. 2017. PMID: 28355432. doi:10.1001/jamacardio.2017.0630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。